One of the best med-tech names out there, Stryker (SYK)
doesn’t have many weaknesses, but the company’s spine business has been
one notable exception. With a portfolio that has been lacking in
innovation or differentiation, Stryker has seen its market share in
spine drift lower against the likes of NuVasive (NUVA) and Globus (GMED) in recent years. Acquiring K2M (KTWO)
is a strong step in shoring up the weakness of Stryker’s spine
business, and while some investors may question Stryker’s decision to
“double down” in a tough business, the long-term benefits of the move
could be larger than they first appear.
Read more here:
K2M Shores Up A Weak Spot For Stryker
No comments:
Post a Comment